Cumulative incidence of 12-month NRM for key subsets using the threshold corresponding to the concordance probability
| Subset . | AUC . | ST2+REG3α . | AUC . | AREG . | ||||
|---|---|---|---|---|---|---|---|---|
| CI 12 mo NRM . | P value . | Correctly classified . | CI 12 mo NRM . | P value . | Correctly classified . | |||
| Validation cohort (n = 374) | ||||||||
| Minnesota high risk (n = 53) | 0.689 | 24% vs 48% | .083 | 29 (55%) | 0.780 | 8% vs 53% | .013 | 33 (62%) |
| Minnesota standard risk (n = 321) | 0.720 | 9% vs 34% | <.001 | 250 (79%) | 0.636 | 11% vs 21% | .003 | 200 (62%) |
| LGI involvement (n = 109) | 0.790 | 12% vs 48% | <.001 | 73 (67%) | 0.773 | 8% vs 45% | <.001 | 66 (61%) |
| Skin only involvement (n = 199) | 0.629 | 8% vs 22% | <.001 | 155 (79%) | 0.563 | 10% vs 13% | .218 | 129 (65%) |
| PT-CY prophylaxis (n = 133) | 0.717 | 12% vs 35% | <.001 | 100 (75%) | 0.595 | 14% vs 21% | .22 | 83 (62%) |
| Systemically treated (n = 321) | 0.739 | 12% vs 39% | <.001 | 231 (72%) | 0.693 | 12% vs 30% | <.001 | 195 (61%) |
| Systemically treated subset (n = 321) | ||||||||
| Minnesota high risk (n = 52) | 0.679 | 26% vs 48% | .116 | 28 (54%) | 0.780 | 8% vs 54% | .011 | 33 (63%) |
| Minnesota standard risk (n = 269) | 0.700 | 12% vs 35% | <.001 | 203 (75%) | 0.617 | 13% vs 23% | .022 | 162 (60%) |
| LGI involvement (n = 104) | 0.777 | 14% vs 49% | <.001 | 68 (65%) | 0.768 | 9% vs 46% | <.001 | 63 (61%) |
| Skin only involvement (n = 158) | 0.610 | 11% vs 24% | .034 | 116 (73%) | 0.555 | 13% vs 16% | .489 | 99 (63%) |
| PT-CY prophylaxis (n = 125) | 0.711 | 13% vs 35% | .005 | 94 (75%) | 0.592 | 16% vs 23% | .233 | 72 (58%) |
| Subset . | AUC . | ST2+REG3α . | AUC . | AREG . | ||||
|---|---|---|---|---|---|---|---|---|
| CI 12 mo NRM . | P value . | Correctly classified . | CI 12 mo NRM . | P value . | Correctly classified . | |||
| Validation cohort (n = 374) | ||||||||
| Minnesota high risk (n = 53) | 0.689 | 24% vs 48% | .083 | 29 (55%) | 0.780 | 8% vs 53% | .013 | 33 (62%) |
| Minnesota standard risk (n = 321) | 0.720 | 9% vs 34% | <.001 | 250 (79%) | 0.636 | 11% vs 21% | .003 | 200 (62%) |
| LGI involvement (n = 109) | 0.790 | 12% vs 48% | <.001 | 73 (67%) | 0.773 | 8% vs 45% | <.001 | 66 (61%) |
| Skin only involvement (n = 199) | 0.629 | 8% vs 22% | <.001 | 155 (79%) | 0.563 | 10% vs 13% | .218 | 129 (65%) |
| PT-CY prophylaxis (n = 133) | 0.717 | 12% vs 35% | <.001 | 100 (75%) | 0.595 | 14% vs 21% | .22 | 83 (62%) |
| Systemically treated (n = 321) | 0.739 | 12% vs 39% | <.001 | 231 (72%) | 0.693 | 12% vs 30% | <.001 | 195 (61%) |
| Systemically treated subset (n = 321) | ||||||||
| Minnesota high risk (n = 52) | 0.679 | 26% vs 48% | .116 | 28 (54%) | 0.780 | 8% vs 54% | .011 | 33 (63%) |
| Minnesota standard risk (n = 269) | 0.700 | 12% vs 35% | <.001 | 203 (75%) | 0.617 | 13% vs 23% | .022 | 162 (60%) |
| LGI involvement (n = 104) | 0.777 | 14% vs 49% | <.001 | 68 (65%) | 0.768 | 9% vs 46% | <.001 | 63 (61%) |
| Skin only involvement (n = 158) | 0.610 | 11% vs 24% | .034 | 116 (73%) | 0.555 | 13% vs 16% | .489 | 99 (63%) |
| PT-CY prophylaxis (n = 125) | 0.711 | 13% vs 35% | .005 | 94 (75%) | 0.592 | 16% vs 23% | .233 | 72 (58%) |
LGI, lower gastrointestinal tract.